Arnulfo Albores

Arnulfo Albores

Auto-generated profile, based on publicly available information

Arnulfo Albores

Departamento de Toxicología Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional Cd. Méx. Mexico

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1983 in Human Toxicology
Verified
Journal Article
Closed access
PDF file
MCMariano E. Cebrian
Mariano E. Cebrian
AAArnulfo Albores
Arnulfo Albores
MAManuel Aguilar
Manuel Aguilar
EBEnrique Blakely
Enrique Blakely
1 We compared the prevalence of signs and symptoms of chronic arsenic poisoning in two rural populations. 2 The arsenic concentration in the drinking water of the exposed population was 0.41 mg/l, and 0.007 mg/l in the control population. 3 The arsenic was present mainly (70%) in its pentavalent form. 4 The objective was to quantitate health effects and risks derived from chronic ingestion of arsenic in contaminated water. 5 In the exposed population, 21.6% of the sample, showed at least one of the cutaneous signs of chronic arsenic poisoning against 2.2% in the control town. 6 Non-specific symptoms were more prevalent in the exposed population and they occurred more frequently in those individuals with skin signs. 7 The relative risk of suffering a particular manifestation of poisoning, ranged from 1.9 to 36 times higher in the exposed population. 8 We estimated the risks above mentioned, which were derived from exposure to minute quantities of arsenic in a known proportion of its oxidation states during a life time period.

1 December 2001 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
Luz Maria Del RazoLuz Maria Del Razo
Luz Maria Del Razo
BQBetzabet Quintanilla-Vega
Betzabet Quintanilla-Vega
EBEduardo Brambila-Colombres
Eduardo Brambila-Colombres
ECEmma S Calderon-Aranda
Emma S Calderon-Aranda
Maurizio MannoMaurizio Manno
Maurizio Manno
AAArnulfo Albores
Arnulfo Albores

1 June 1997 in Mutation Research - Reviews in Mutation Research
Verified
Journal Article
Closed access
MGM.E. Gonsebatt
M.E. Gonsebatt
LVLibia Vega
Libia Vega
ASA.M. Salazar
A.M. Salazar
RMR. Montero
R. Montero
PGP. Guzmán
P. Guzmán
POP. Ostrosky-Wegman
P. Ostrosky-Wegman

13 March 1997 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
Luz Maria Del RazoLuz Maria Del Razo
Luz Maria Del Razo
GGG. G. García-Vargas
G. G. García-Vargas
AAA. Albores
A. Albores
HVH. Vargas
H. Vargas
MGM. E. Gonsebatt
M. E. Gonsebatt
MCM. E. Cebrián
M. E. Cebrián

1 January 2005 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
MCMartha Patricia Cervantes-Cervantes
Martha Patricia Cervantes-Cervantes
JCJ. Víctor Calderón-Salinas
J. Víctor Calderón-Salinas
AAArnulfo Albores
Arnulfo Albores
JMJosé Luis Muñoz-Sánchez
José Luis Muñoz-Sánchez

1 June 1999 in Pharmacogenetics
Verified
Journal Article
Closed access
DLDaniele Lucas
Daniele Lucas
RFRoberta Ferrara
Roberta Ferrara
EGEva Gonzalez
Eva Gonzalez
PBPierre Bodenez
Pierre Bodenez
AAArnulfo Albores
Arnulfo Albores
FBFrancois Berthou
Francois Berthou
The ability of human cytochromes P450 other than CYP2E1 to catalyse the 6-hydroxylation of chlorzoxazone (6-OH-CHZ) was examined in vitro using human liver microsomal preparations and in vivo using chlorzoxazone as a metabolic probe. Chlorzoxazone 6-hydroxylation activity was significantly correlated with 4-nitrophenol 2-hydroxylase activity and immunodetected CYP2E1 in 14 human liver samples (r = 0.92 and 0.81, P < 0.001, respectively). Conversely, this catalytic activity was not correlated with CYP 3A or CYP1A activities. Diethyldithiocarbamate (DEDTC), a specific CYP2E1 inhibitor, reduced chlorzoxazone 6-hydroxylase activity by 92.3 ± 7.6% (n = 14 samples) while ketoconazole, a specific CYP3A inhibitor, reduced this activity by 8.6 ± 6.3% (n = 14). The residual activity following preincubation with DEDTC was significantly correlated with nifedipine oxidation and tamoxifen N-demethylations, both specific to CYP3A (r = 0.76 and 0.68, respectively). Genetically produced pure human CYP2E1 and 3A4 hydroxylated chlorzoxazone with turnover numbers of 19.7 and 0.14 min-1, respectively. Furthermore, cytochrome b5 stimulated chlorzoxazone 6-hydroxylation. From examination of the relative liver content of CYP2E1 and 3A, it can be asserted that CYP2E1 is the major enzyme involved in chlorzoxazone 6-hydroxylation and that the contribution of CYP3A is very minor. CYP2E1 activity was evaluated by the plasmatic metabolic ratio 6-OH-CHZ/CHZ (CHZ-MR) measured 2 h after ingestion of 500 mg CHZ. Smoker status did not influence the rate of CHZ hydroxylation. The CHZ-MR was 0.30 ± 0.13 (mean ± SD) n = 39 non-smokers versus 0.32 ± 0.15, n = 75 smokers. This result suggests that CYP1A, inducible by cigarette smoking, is not significantly involved in chlorzoxazone hydroxylation. Women exhibited a slightly lower CHZ-MR than men (0.29 ± 0.15, n = 44 versus 0.34 ± 0.15 n = 49, respectively). Obesity increased CHZ-MR, especially in non-insulindependent diabetic individuals (0.45 ± 0.21, n = 13 versus 0.30 ± 0.15, n = 42 control individuals, P = 0.007). Furthermore, exposure of workers to volatile organics in a shoe factory decreased CHZ-MR (0.19 ± 0.09, n = 10 Mexican workers versus 0.34 ± 0.12, n = 16 Mexican control individuals, P = 0.001). Concomitant administration of grapefruit juice (known to be an inhibitor of CYP3A4) with chlorzoxazone did not significantly modify the CHZ metabolic ratio: 0.29 ± 0.1 versus 0.31 ± 0.1, for nine control individuals without and with grapefruit juice, respectively. In conclusion, all these results demonstrate that chlorzoxazone is a very selective probe for phenotyping CYP2E1 in humans.